KM
Therapeutic Areas
Sumitomo Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LATUDA (lurasidone HCl) | Major Depressive Disorder associated with bipolar I depression | Approved/Commercial |
| REXULTI (brexpiprazole) | Adjunctive treatment of Major Depressive Disorder | Approved/Commercial |
| Vibegron | Overactive Bladder | Approved/Commercial |
| ORGOVYX (relugolix) | Advanced Prostate Cancer | Approved/Commercial |
| MYFEMBREE (relugolix/estradiol/norethindrone) | Uterine Fibroids & Endometriosis Pain | Approved/Commercial |
| DSP-0187 | Acute Treatment of Schizophrenia | Phase 3 |
| DSP-1181 (pimavanserin) | Alzheimer's Disease Psychosis | Phase 3 |
| SP-1032 | Chronic Lower Back Pain | Phase 3 |
Leadership Team at Sumitomo Pharma
HN
Hiroshi Nomura
Representative Director, President and Chief Executive Officer
TK
Toru Kimura
Director, Senior Managing Executive Officer, Chief Financial Officer
ST
Satoshi Tanaka
Director, Senior Managing Executive Officer, Chief Strategy Officer
MS
Myrtle S. Potter
Director, Senior Managing Executive Officer, Chief Commercial Officer (Sumitomo Pharma America)
NT
Nobuhiko Tamura
Director, Senior Managing Executive Officer, Chief Medical Officer
YO
Yoshihiro Ohta
Director, Senior Managing Executive Officer
YY
Yoshiharu Yamaguchi
Director, Senior Managing Executive Officer
KH
Kazunori Hirokawa
Director, Managing Executive Officer, Head of Japan Business
KO
Koichi Oshima
Director, Managing Executive Officer, Head of Corporate Strategy & Planning
AO
Atsushi Otsuka
Director, Managing Executive Officer, Head of Research & Development